Acrivon Therapeutics Inc (ACRV) Price to Earnings Ratio

Corporate emblem and logo of Acrivon (ACRV)

Acrivon Therapeutics (ACRV) revenues rely on the development of oncology therapies via the AP3 system, where the primary catalyst will be the sale of selective agents for treating bladder and ovarian tumors. A technological leap is driven by precision proteomics and the implementation of CHK1/2 inhibitors. The available price action vector with the -0.80 indicator confirms the resilience of a non-cyclical business dependent on clinical success rather than market conditions.

Acrivon Therapeutics Inc (ACRV): Price to Earnings Ratio from 04/28/2023 to 11/14/2026

Analytical breakdowns for Acrivon Therapeutics

- stock quotes and analyst forecast:
Price Chart acrivon.com|ACRV - Price Target Chart
- market capitalization details:
Market Value Acrivon Therapeutics, Inc.|ACRV - Enterprise Value
- book capitalization information:
Book Value per Share Acrivon Therapeutics|ACRV - Company Book Value|Capitalization to Book Value Ratio acrivon.com|ACRV - Company Total Assets
- debt and solvency information:
Debt to Capital Acrivon Therapeutics|ACRV - Long-Term Debt to Equity|Current Liabilities to Capital Acrivon Pharma|ACRV - Company Total Debt|Debts to Book Capitalization Acrivon Therapeutics, Inc.|ACRV - Company Long-Term Debt|Short-Term Debt Volume Acrivon Therapeutics|Intermediate Coverage Ratio acrivon.com
- net income and valuation ratios data:
ACRV - Company Net Income|Expected Net Profit Acrivon Therapeutics|ACRV - Price to Earnings Ratio|Price to Future Earnings Ratio Acrivon Therapeutics Inc|ACRV - PEG Multiple|Enterprise Value to EBITDA Ratio Acrivon Therapeutics, Inc.|ACRV - Profit before payment of interest, taxes and amortization|Net earnings per one share for the last twelve months Acrivon Therapeutics|ACRV - Earnings per share for the last twelve months|Year-over-year earnings per share growth for the last twelve months acrivon.com|ACRV - Earnings per share growth in current year|Expected net earnings per share growth next year Acrivon Therapeutics
- sales volume and revenue indicators:
ACRV - Revenue and Sales Volume|Company Sales Forecast acrivon.com|ACRV - Market Cap to Revenue|Market Cap to Future Revenue Ratio Acrivon Therapeutics, Inc.
General company analysis:ACRV, acrivon.com
Original product of Acrivon Therapeutics, Inc.

The P/E ratio determines the market value of a single unit of net profit, allowing an investor to assess the extent of overpayment for an asset relative to its actual yield. By analyzing the market valuation via P/E, one can compare financial expectations with the management efficiency of the Acrivon Therapeutics (ACRV) precision oncology platform and the quality of their clinical trials to identify an unjustified price bubble in a timely manner.

Analysis of competing companies

Price to Earnings Ratio NVCR|Price to Earnings Ratio Alpha Tau Medical (DRTS)|Price to Earnings Ratio FBIO (Fortress Biotech Inc)|P/E Multiple ALLR (Allarity Therapeutics, Inc.)